(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 July 2014 (31.07.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/116275 A1

(51) International Patent Classification:
A61K 38/48 (2006.01) *C07K 14/745* (2006.01)
A61K 47/48 (2006.01) *C12N 9/64* (2006.01)

(21) International Application Number:
PCT/US2013/030927

(22) International Filing Date:
13 March 2013 (13.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/756,359 24 January 2013 (24.01.2013) US

(71) Applicant: **PORTOLA PHARMACEUTICALS, INC.** [US/US]; 270 E. Grand Avenue, South San Francisco, California 94080 (US).

(72) Inventors: **LU, Genmin**; 1439 El Camino Real, Apt 9, Burlingame, California 94010 (US). **SINHA, Uma**; 808 Junipero Serra Blvd., San Francisco, California 94127 (US). **KARBARZ, Mark**; 2829 Las Piedras Drive, Burlingame, California 94010 (US). **PANDEY, Anjali**; 4506 Amiens Avenue, Fremont, California 94555 (US). **CONLEY, Pamela, B.**; 116 Lois Lane, Palo Alto, California 94303 (US).

(74) Agents: **TANNER, Lorna, L.** et al.; Foley & Lardner LLP, 3000 K Street N.W., Suite 600, Washington, District of Columbia 20007-5109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

[Continued on next page]

(54) Title: INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES




FIG. 1C

(57) Abstract: The present disclosure relates to compositions and methods for the treatment of bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand (vWF) disease, and factor XII deficiency, by reducing the circulating concentration of tissue factor pathway inhibitor (TFPI), with a factor Xa derivative.

WO 2014/116275 A1

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*